Primary | Change in CBI after 4 weeks of treatment |
---|---|
Secondary | 1. Change in plaque morphology by virtual |
 | histology at 4 weeks as assessed by IVUS |
 | 2. Change in myocardial perfusion at 4 weeks and |
 | 12 months as assessed by adenosine MRI |
 | 3. MACE at 1, 3, 6 and 12 months |
 | 4. Hospitalization due to cardiovascular causes |
 | 5. Change in atherosclerotic parameters (hs-CRP, |
 | ADMA, endostatin, EPC, ox LDL, cytokines, |
 | adiponectine), lipid status and glucose status |
 | 6. Change in exercise capacity (ergospirometry) and |
 | V02 peak |